Oleandrin - DrugBank

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name

Oleandrin

Accession Number

DB12843

Type

Small Molecule

Groups

Experimental

Description

Oleandrin has been used in trials studying the treatment of Lung Cancer and Chemotherapeutic Agent Toxicity.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Anvirzel

Oleandrina

External IDs

NSC-692219

Product Ingredients

Not Available

Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

II95UDU7I4

CAS number

465-16-7

Weight

Average: 576.727
Monoisotopic: 576.329833126

Chemical Formula

C₃₂H₄₈O₉

InChI Key

JLPDBLFIVFSOCC-XYXFTTADSA-N

InChI

InChI=1S/C32H48O9/c1-17-29(35)24(37-5)14-27(39-17)41-21-8-10-30(3)20(13-21)6-7-23-22(30)9-11-31(4)28(19-12-26(34)38-16-19)25(40-18(2)33)15-32(23,31)36/h12,17,20-25,27-29,35-36H,6-11,13-16H2,1-5H3/t17-,20+,21-,22-,23+,24-,25-,27-,28-,29-,30-,31+,32-/m0/s1

IUPAC Name

(1S,2S,5S,7R,10R,11S,13S,14R,15R)-11-hydroxy-5-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-2,15-dimethyl-14-(5-oxo-2,5-dihydrofuran-3-yl)tetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadecan-13-yl acetate

SMILES

CO[[email protected]]1C[[email protected]](O[[email protected]]2CC[[email protected]@]3(C)[[email protected]](CC[[email protected]@H]4[[email protected]@H]3CC[[email protected]]3(C)[[email protected]]([[email protected]](C[[email protected]]43O)OC(C)=O)C3=CC(=O)OC3)C2)O[[email protected]@H](C)[[email protected]@H]1O

Pharmacology

Indication

Not Available

Structured Indications

Not Available

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide	Anvirzel may decrease the cardiotoxic activities of 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.	Experimental
2-Methoxyestradiol	Anvirzel may decrease the cardiotoxic activities of 2-Methoxyestradiol.	Investigational
3-Methoxybenzamide	Anvirzel may decrease the cardiotoxic activities of 3-Methoxybenzamide.	Experimental
3,3'-diindolylmethane	Anvirzel may decrease the cardiotoxic activities of Diindolylmethane.	Investigational
3,4-Dihydroxybenzoic Acid	Anvirzel may decrease the cardiotoxic activities of 3,4-Dihydroxybenzoic Acid.	Experimental
7-Hydroxystaurosporine	Anvirzel may decrease the cardiotoxic activities of 7-Hydroxystaurosporine.	Experimental
8-azaguanine	Anvirzel may decrease the cardiotoxic activities of 8-azaguanine.	Experimental
9-aminocamptothecin	Anvirzel may decrease the cardiotoxic activities of Aminocamptothecin.	Investigational
Abiraterone	Anvirzel may decrease the cardiotoxic activities of Abiraterone.	Approved
Acebutolol	Acebutolol may increase the bradycardic activities of Anvirzel.	Approved
Aclarubicin	Anvirzel may decrease the cardiotoxic activities of Aclarubicin.	Investigational
Acteoside	Anvirzel may decrease the cardiotoxic activities of Acteoside.	Investigational
Afatinib	Anvirzel may decrease the cardiotoxic activities of Afatinib.	Approved
Afimoxifene	Anvirzel may decrease the cardiotoxic activities of Afimoxifene.	Investigational
Aflibercept	Anvirzel may decrease the cardiotoxic activities of Aflibercept.	Approved
Alatrofloxacin	Anvirzel may decrease the cardiotoxic activities of Alatrofloxacin.	Withdrawn
Albendazole	Anvirzel may decrease the cardiotoxic activities of Albendazole.	Approved, Vet Approved
Aldesleukin	Anvirzel may decrease the cardiotoxic activities of Aldesleukin.	Approved
Alemtuzumab	Anvirzel may decrease the cardiotoxic activities of Alemtuzumab.	Approved, Investigational
Alfacalcidol	Alfacalcidol may increase the arrhythmogenic activities of Anvirzel.	Approved, Nutraceutical
Alitretinoin	Anvirzel may decrease the cardiotoxic activities of Alitretinoin.	Approved, Investigational
Alprenolol	Alprenolol may increase the bradycardic activities of Anvirzel.	Approved, Withdrawn
Altretamine	Anvirzel may decrease the cardiotoxic activities of Altretamine.	Approved
Alvocidib	Anvirzel may decrease the cardiotoxic activities of Flavopiridol.	Experimental, Investigational
Amikacin	The serum concentration of Anvirzel can be decreased when it is combined with Amikacin.	Approved, Vet Approved
Amiloride	The therapeutic efficacy of Anvirzel can be decreased when used in combination with Amiloride.	Approved
Aminoglutethimide	Anvirzel may decrease the cardiotoxic activities of Aminoglutethimide.	Approved
Aminolevulinic acid	Anvirzel may decrease the cardiotoxic activities of Aminolevulinic acid.	Approved
Amiodarone	The serum concentration of Anvirzel can be increased when it is combined with Amiodarone.	Approved, Investigational
Amodiaquine	The serum concentration of Anvirzel can be increased when it is combined with Amodiaquine.	Approved
Amonafide	Anvirzel may decrease the cardiotoxic activities of Amonafide.	Investigational
Amphotericin B	The risk or severity of adverse effects can be increased when Amphotericin B is combined with Anvirzel.	Approved, Investigational
Amrubicin	Anvirzel may decrease the cardiotoxic activities of Amrubicin.	Approved, Investigational
Amsacrine	Anvirzel may decrease the cardiotoxic activities of Amsacrine.	Approved
Anagrelide	Anvirzel may decrease the cardiotoxic activities of Anagrelide.	Approved
Anastrozole	Anvirzel may decrease the cardiotoxic activities of Anastrozole.	Approved, Investigational
Anecortave	Anvirzel may decrease the cardiotoxic activities of Anecortave.	Investigational
annamycin	Anvirzel may decrease the cardiotoxic activities of annamycin.	Investigational
AP 12009	Anvirzel may decrease the cardiotoxic activities of AP 12009.	Investigational
AP24534	Anvirzel may decrease the cardiotoxic activities of AP24534.	Investigational
Apaziquone	Anvirzel may decrease the cardiotoxic activities of Apaziquone.	Investigational
Apramycin	The serum concentration of Anvirzel can be decreased when it is combined with Apramycin.	Experimental, Vet Approved
Arbekacin	The serum concentration of Anvirzel can be decreased when it is combined with Arbekacin.	Approved
Arotinolol	Arotinolol may increase the bradycardic activities of Anvirzel.	Approved
Arsenic trioxide	Anvirzel may decrease the cardiotoxic activities of Arsenic trioxide.	Approved, Investigational
Asparaginase	Anvirzel may decrease the cardiotoxic activities of Asparaginase.	Approved
Atenolol	Atenolol may increase the bradycardic activities of Anvirzel.	Approved
Atracurium besylate	Atracurium besylate may increase the arrhythmogenic activities of Anvirzel.	Approved
Axitinib	Anvirzel may decrease the cardiotoxic activities of Axitinib.	Approved, Investigational
Azacitidine	Anvirzel may decrease the cardiotoxic activities of Azacitidine.	Approved, Investigational
Azathioprine	Anvirzel may decrease the cardiotoxic activities of Azathioprine.	Approved
AZD-4547	Anvirzel may decrease the cardiotoxic activities of Azd4547.	Investigational
Azelaic Acid	Anvirzel may decrease the cardiotoxic activities of Azelaic Acid.	Approved
Azithromycin	The serum concentration of Anvirzel can be increased when it is combined with Azithromycin.	Approved
Balsalazide	The serum concentration of Anvirzel can be decreased when it is combined with Balsalazide.	Approved, Investigational
Batimastat	Anvirzel may decrease the cardiotoxic activities of Batimastat.	Experimental
Befunolol	Befunolol may increase the bradycardic activities of Anvirzel.	Experimental
Belinostat	Anvirzel may decrease the cardiotoxic activities of Belinostat.	Approved, Investigational
Belotecan	Anvirzel may decrease the cardiotoxic activities of Belotecan.	Investigational
Bendamustine	Anvirzel may decrease the cardiotoxic activities of Bendamustine.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Anvirzel.	Approved
Besifloxacin	Anvirzel may decrease the cardiotoxic activities of Besifloxacin.	Approved
Betaxolol	Betaxolol may increase the bradycardic activities of Anvirzel.	Approved
Betulinic Acid	Anvirzel may decrease the cardiotoxic activities of Betulinic Acid.	Investigational
Bevacizumab	Anvirzel may decrease the cardiotoxic activities of Bevacizumab.	Approved, Investigational
Bevantolol	Bevantolol may increase the bradycardic activities of Anvirzel.	Approved
Bexarotene	Anvirzel may decrease the cardiotoxic activities of Bexarotene.	Approved, Investigational
Bicalutamide	Anvirzel may decrease the cardiotoxic activities of Bicalutamide.	Approved
Binetrakin	Anvirzel may decrease the cardiotoxic activities of Il 4.	Investigational
Bisoprolol	Bisoprolol may increase the bradycardic activities of Anvirzel.	Approved
Bizelesin	Anvirzel may decrease the cardiotoxic activities of Bizelesin.	Investigational
Bleomycin	Anvirzel may decrease the cardiotoxic activities of Bleomycin.	Approved
Blinatumomab	Anvirzel may decrease the cardiotoxic activities of Blinatumomab.	Approved
Bopindolol	Bopindolol may increase the bradycardic activities of Anvirzel.	Approved
Bortezomib	Anvirzel may decrease the cardiotoxic activities of Bortezomib.	Approved, Investigational
Bosutinib	Anvirzel may decrease the cardiotoxic activities of Bosutinib.	Approved
Brentuximab vedotin	Anvirzel may decrease the cardiotoxic activities of Brentuximab vedotin.	Approved
Broxuridine	Anvirzel may decrease the cardiotoxic activities of Broxuridine.	Investigational
Bryostatin 1	Anvirzel may decrease the cardiotoxic activities of Bryostatin 1.	Investigational
BSI-201	Anvirzel may decrease the cardiotoxic activities of BSI-201.	Investigational
Bucindolol	Bucindolol may increase the bradycardic activities of Anvirzel.	Investigational
Bufuralol	Bufuralol may increase the bradycardic activities of Anvirzel.	Experimental, Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Bumetanide is combined with Anvirzel.	Approved
Bupranolol	Bupranolol may increase the bradycardic activities of Anvirzel.	Approved
Busulfan	Anvirzel may decrease the cardiotoxic activities of Busulfan.	Approved, Investigational
Buthionine Sulfoximine	Anvirzel may decrease the cardiotoxic activities of Buthionine Sulfoximine.	Investigational
Cabazitaxel	Anvirzel may decrease the cardiotoxic activities of Cabazitaxel.	Approved
Cabergoline	Anvirzel may decrease the cardiotoxic activities of Cabergoline.	Approved
Cabozantinib	Anvirzel may decrease the cardiotoxic activities of Cabozantinib.	Approved
Calcidiol	Calcidiol may increase the arrhythmogenic activities of Anvirzel.	Approved, Nutraceutical
Calcipotriol	Anvirzel may decrease the cardiotoxic activities of Calcipotriol.	Approved
Calcitriol	Calcitriol may increase the arrhythmogenic activities of Anvirzel.	Approved, Nutraceutical
Calcium	Calcium may increase the arrhythmogenic activities of Anvirzel.	Nutraceutical
Calcium Acetate	Calcium Acetate may increase the arrhythmogenic activities of Anvirzel.	Approved
Calcium Carbonate	Calcium carbonate may increase the arrhythmogenic activities of Anvirzel.	Approved
Calcium Chloride	Calcium Chloride may increase the arrhythmogenic activities of Anvirzel.	Approved
Calcium Citrate	Calcium citrate may increase the arrhythmogenic activities of Anvirzel.	Approved
Calcium glubionate	Calcium glubionate may increase the arrhythmogenic activities of Anvirzel.	Approved
Calcium Gluceptate	Calcium Gluceptate may increase the arrhythmogenic activities of Anvirzel.	Approved
Calcium gluconate	Calcium gluconate may increase the arrhythmogenic activities of Anvirzel.	Approved, Vet Approved
Camptothecin	Anvirzel may decrease the cardiotoxic activities of Camptothecin.	Experimental
Capecitabine	Anvirzel may decrease the cardiotoxic activities of Capecitabine.	Approved, Investigational
Carbimazole	The serum concentration of Anvirzel can be increased when it is combined with Carbimazole.	Approved
Carbomycin	The serum concentration of Anvirzel can be increased when it is combined with Carbomycin.	Vet Approved
Carboplatin	Anvirzel may decrease the cardiotoxic activities of Carboplatin.	Approved
Carbopol 974P	Anvirzel may decrease the cardiotoxic activities of polyacrylic acid.	Investigational
Carboxyamidotriazole	Anvirzel may decrease the cardiotoxic activities of Cai.	Investigational
Carfilzomib	Anvirzel may decrease the cardiotoxic activities of Carfilzomib.	Approved
Carmofur	Anvirzel may decrease the cardiotoxic activities of Carmofur.	Withdrawn
Carmustine	Anvirzel may decrease the cardiotoxic activities of Carmustine.	Approved
Carteolol	Carteolol may increase the bradycardic activities of Anvirzel.	Approved
Carvedilol	Carvedilol may increase the bradycardic activities of Anvirzel.	Approved, Investigational
Catumaxomab	Anvirzel may decrease the cardiotoxic activities of Catumaxomab.	Investigational
Cediranib	Anvirzel may decrease the cardiotoxic activities of AZD2171.	Investigational
Celecoxib	Anvirzel may decrease the cardiotoxic activities of Celecoxib.	Approved, Investigational
Celiprolol	Celiprolol may increase the bradycardic activities of Anvirzel.	Approved, Investigational
Ceritinib	Anvirzel may decrease the cardiotoxic activities of Ceritinib.	Approved
Cetuximab	Anvirzel may decrease the cardiotoxic activities of Cetuximab.	Approved
Chlorambucil	Anvirzel may decrease the cardiotoxic activities of Chlorambucil.	Approved
Chloroquine	The serum concentration of Anvirzel can be increased when it is combined with Chloroquine.	Approved, Vet Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Anvirzel.	Approved, Vet Approved
Chlorotrianisene	Anvirzel may decrease the cardiotoxic activities of Chlorotrianisene.	Withdrawn
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Anvirzel.	Approved
Cholecalciferol	Cholecalciferol may increase the arrhythmogenic activities of Anvirzel.	Approved, Nutraceutical
Cholestyramine	Cholestyramine can cause a decrease in the absorption of Anvirzel resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Cinoxacin	Anvirzel may decrease the cardiotoxic activities of Cinoxacin.	Approved, Withdrawn
Ciprofloxacin	Anvirzel may decrease the cardiotoxic activities of Ciprofloxacin.	Approved, Investigational
Cisatracurium besylate	Cisatracurium besylate may increase the arrhythmogenic activities of Anvirzel.	Approved
Cisplatin	Anvirzel may decrease the cardiotoxic activities of Cisplatin.	Approved
Cladribine	Anvirzel may decrease the cardiotoxic activities of Cladribine.	Approved, Investigational
Clarithromycin	The serum concentration of Anvirzel can be increased when it is combined with Clarithromycin.	Approved
Clofarabine	Anvirzel may decrease the cardiotoxic activities of Clofarabine.	Approved, Investigational
Clonidine	Clonidine may increase the atrioventricular blocking (AV block) activities of Anvirzel.	Approved
Colchicine	Anvirzel may decrease the cardiotoxic activities of Colchicine.	Approved
Colesevelam	Colesevelam can cause a decrease in the absorption of Anvirzel resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Colestipol	Colestipol can cause a decrease in the absorption of Anvirzel resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved
Cordycepin	Anvirzel may decrease the cardiotoxic activities of Cordycepin.	Investigational
Crenolanib	Anvirzel may decrease the cardiotoxic activities of Crenolanib.	Investigational
Crizotinib	Anvirzel may decrease the cardiotoxic activities of Crizotinib.	Approved
Curcumin	Anvirzel may decrease the cardiotoxic activities of Curcumin.	Investigational
Cyclophosphamide	Anvirzel may decrease the cardiotoxic activities of Cyclophosphamide.	Approved, Investigational
Cyproterone acetate	Anvirzel may decrease the cardiotoxic activities of Cyproterone acetate.	Approved, Investigational
Cytarabine	Anvirzel may decrease the cardiotoxic activities of Cytarabine.	Approved, Investigational
Dabrafenib	Anvirzel may decrease the cardiotoxic activities of Dabrafenib.	Approved
Dacarbazine	Anvirzel may decrease the cardiotoxic activities of Dacarbazine.	Approved, Investigational
Dactinomycin	Anvirzel may decrease the cardiotoxic activities of Dactinomycin.	Approved
Daratumumab	Anvirzel may decrease the cardiotoxic activities of Daratumumab.	Approved
Dasatinib	Anvirzel may decrease the cardiotoxic activities of Dasatinib.	Approved, Investigational
Daunorubicin	Anvirzel may decrease the cardiotoxic activities of Daunorubicin.	Approved
Decamethonium	Decamethonium may increase the arrhythmogenic activities of Anvirzel.	Approved
Decitabine	Anvirzel may decrease the cardiotoxic activities of Decitabine.	Approved, Investigational
Denileukin diftitox	Anvirzel may decrease the cardiotoxic activities of Denileukin diftitox.	Approved, Investigational
Deoxyspergualin	Anvirzel may decrease the cardiotoxic activities of Deoxyspergualin.	Investigational
Dexamethasone	Anvirzel may decrease the cardiotoxic activities of Dexamethasone.	Approved, Investigational, Vet Approved
Dexrazoxane	Anvirzel may decrease the cardiotoxic activities of Dexrazoxane.	Approved, Withdrawn
Dianhydrogalactitol	Anvirzel may decrease the cardiotoxic activities of Val 083.	Investigational
Dienogest	Anvirzel may decrease the cardiotoxic activities of Dienogest.	Approved
Diethylstilbestrol	Anvirzel may decrease the cardiotoxic activities of Diethylstilbestrol.	Approved
Dihydrostreptomycin	The serum concentration of Anvirzel can be decreased when it is combined with Dihydrostreptomycin.	Vet Approved
Dihydrotachysterol	Dihydrotachysterol may increase the arrhythmogenic activities of Anvirzel.	Approved
Diltiazem	Diltiazem may increase the atrioventricular blocking (AV block) activities of Anvirzel.	Approved
Dinutuximab	Anvirzel may decrease the cardiotoxic activities of Dinutuximab.	Approved
Docetaxel	Anvirzel may decrease the cardiotoxic activities of Docetaxel.	Approved, Investigational
Domoic Acid	Domoic Acid may increase the arrhythmogenic activities of Anvirzel.	Experimental
Doxacurium chloride	Doxacurium chloride may increase the arrhythmogenic activities of Anvirzel.	Approved
Doxercalciferol	Doxercalciferol may increase the arrhythmogenic activities of Anvirzel.	Approved
Doxifluridine	Anvirzel may decrease the cardiotoxic activities of Doxifluridine.	Investigational
Doxorubicin	Anvirzel may decrease the cardiotoxic activities of Doxorubicin.	Approved, Investigational
Ecabet	Anvirzel may decrease the cardiotoxic activities of Ecabet.	Approved, Investigational
Edrophonium	Edrophonium may increase the atrioventricular blocking (AV block) activities of Anvirzel.	Approved
Eflornithine	Anvirzel may decrease the cardiotoxic activities of Eflornithine.	Approved, Withdrawn
EG009	Anvirzel may decrease the cardiotoxic activities of EG009.	Investigational
Elsamitrucin	Anvirzel may decrease the cardiotoxic activities of Elsamitrucin.	Investigational
Endostatin	Anvirzel may decrease the cardiotoxic activities of Endostatin.	Investigational
Enoxacin	Anvirzel may decrease the cardiotoxic activities of Enoxacin.	Approved
Enrofloxacin	Anvirzel may decrease the cardiotoxic activities of Enrofloxacin.	Vet Approved
Entinostat	Anvirzel may decrease the cardiotoxic activities of Entinostat.	Investigational
Epirubicin	Anvirzel may decrease the cardiotoxic activities of Epirubicin.	Approved
Eplerenone	The therapeutic efficacy of Anvirzel can be decreased when used in combination with Eplerenone.	Approved
Epofolate	Anvirzel may decrease the cardiotoxic activities of Epofolate.	Investigational
Ergocalciferol	Ergocalciferol may increase the arrhythmogenic activities of Anvirzel.	Approved, Nutraceutical
Eribulin	Anvirzel may decrease the cardiotoxic activities of Eribulin.	Approved, Investigational
Erlotinib	Anvirzel may decrease the cardiotoxic activities of Erlotinib.	Approved, Investigational
Erythromycin	The serum concentration of Anvirzel can be increased when it is combined with Erythromycin.	Approved, Vet Approved
Esmolol	Esmolol may increase the bradycardic activities of Anvirzel.	Approved
Estramustine	Anvirzel may decrease the cardiotoxic activities of Estramustine.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Anvirzel.	Approved
Etanidazole	Anvirzel may decrease the cardiotoxic activities of Etanidazole.	Investigational
Ethiodized oil	Anvirzel may decrease the cardiotoxic activities of Ethiodized oil.	Approved
Ethyl carbamate	Anvirzel may decrease the cardiotoxic activities of Ethyl carbamate.	Withdrawn
Etoposide	Anvirzel may decrease the cardiotoxic activities of Etoposide.	Approved
Everolimus	Anvirzel may decrease the cardiotoxic activities of Everolimus.	Approved
Exatecan	Anvirzel may decrease the cardiotoxic activities of Exatecan.	Investigational
Exemestane	Anvirzel may decrease the cardiotoxic activities of Exemestane.	Approved, Investigational
exisulind	Anvirzel may decrease the cardiotoxic activities of exisulind.	Investigational
Fenretinide	Anvirzel may decrease the cardiotoxic activities of Fenretinide.	Investigational
Fiacitabine	Anvirzel may decrease the cardiotoxic activities of Fiacitabine.	Investigational
Fleroxacin	Anvirzel may decrease the cardiotoxic activities of Fleroxacin.	Approved
Floxuridine	Anvirzel may decrease the cardiotoxic activities of Floxuridine.	Approved
Fludarabine	Anvirzel may decrease the cardiotoxic activities of Fludarabine.	Approved
Flumequine	Anvirzel may decrease the cardiotoxic activities of Flumequine.	Withdrawn
Fluorouracil	Anvirzel may decrease the cardiotoxic activities of Fluorouracil.	Approved
Flutamide	Anvirzel may decrease the cardiotoxic activities of Flutamide.	Approved
Formestane	Anvirzel may decrease the cardiotoxic activities of Formestane.	Approved, Investigational, Withdrawn
Formycin	Anvirzel may decrease the cardiotoxic activities of Formycin.	Experimental
Fotemustine	Anvirzel may decrease the cardiotoxic activities of Fotemustine.	Experimental
Framycetin	The serum concentration of Anvirzel can be decreased when it is combined with Framycetin.	Approved
Fulvestrant	Anvirzel may decrease the cardiotoxic activities of Fulvestrant.	Approved, Investigational
Fumagillin	Anvirzel may decrease the cardiotoxic activities of Fumagillin.	Experimental
Furosemide	The risk or severity of adverse effects can be increased when Furosemide is combined with Anvirzel.	Approved, Vet Approved
Gallamine Triethiodide	Gallamine Triethiodide may increase the arrhythmogenic activities of Anvirzel.	Approved
Gallium nitrate	Anvirzel may decrease the cardiotoxic activities of Gallium nitrate.	Approved, Investigational
Garenoxacin	Anvirzel may decrease the cardiotoxic activities of Garenoxacin.	Investigational
Gatifloxacin	Anvirzel may decrease the cardiotoxic activities of Gatifloxacin.	Approved, Investigational
Gefitinib	Anvirzel may decrease the cardiotoxic activities of Gefitinib.	Approved, Investigational
Geldanamycin	Anvirzel may decrease the cardiotoxic activities of Geldanamycin.	Experimental
Gemcitabine	Anvirzel may decrease the cardiotoxic activities of Gemcitabine.	Approved
Gemifloxacin	Anvirzel may decrease the cardiotoxic activities of Gemifloxacin.	Approved, Investigational
Gemtuzumab ozogamicin	Anvirzel may decrease the cardiotoxic activities of Gemtuzumab ozogamicin.	Approved
Geneticin	The serum concentration of Anvirzel can be decreased when it is combined with Geneticin.	Experimental
Genistein	Anvirzel may decrease the cardiotoxic activities of Genistein.	Investigational
Gentamicin	The serum concentration of Anvirzel can be decreased when it is combined with Gentamicin.	Approved, Vet Approved
GENTAMICIN C1A	The serum concentration of Anvirzel can be decreased when it is combined with GENTAMICIN C1A.	Experimental
Ginsenoside C	Anvirzel may decrease the cardiotoxic activities of Ginsenoside C.	Nutraceutical
Goserelin	Anvirzel may decrease the cardiotoxic activities of Goserelin.	Approved
Grepafloxacin	Anvirzel may decrease the cardiotoxic activities of Grepafloxacin.	Withdrawn
GS 0573	Anvirzel may decrease the cardiotoxic activities of 9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine.	Investigational
Gusperimus	Anvirzel may decrease the cardiotoxic activities of Gusperimus.	Investigational
Hadacidin	Anvirzel may decrease the cardiotoxic activities of Hadacidin.	Experimental
Halofuginone	Anvirzel may decrease the cardiotoxic activities of Halofuginone.	Investigational, Vet Approved
Hexestrol	Anvirzel may decrease the cardiotoxic activities of Hexestrol.	Withdrawn
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Anvirzel.	Approved, Vet Approved
Hydroflumethiazide	The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Anvirzel.	Approved
Hydroxychloroquine	The serum concentration of Anvirzel can be increased when it is combined with Hydroxychloroquine.	Approved
Hydroxyprogesterone caproate	Anvirzel may decrease the cardiotoxic activities of Hydroxyprogesterone caproate.	Approved
Hydroxyurea	Anvirzel may decrease the cardiotoxic activities of Hydroxyurea.	Approved
Hygromycin B	The serum concentration of Anvirzel can be decreased when it is combined with Hygromycin B.	Vet Approved
Ibrutinib	Anvirzel may decrease the cardiotoxic activities of Ibrutinib.	Approved
Idarubicin	Anvirzel may decrease the cardiotoxic activities of Idarubicin.	Approved
Idelalisib	Anvirzel may decrease the cardiotoxic activities of Idelalisib.	Approved
Ifosfamide	Anvirzel may decrease the cardiotoxic activities of Ifosfamide.	Approved
Imatinib	Anvirzel may decrease the cardiotoxic activities of Imatinib.	Approved
Imiquimod	Anvirzel may decrease the cardiotoxic activities of Imiquimod.	Approved, Investigational
Indapamide	The risk or severity of adverse effects can be increased when Indapamide is combined with Anvirzel.	Approved
Indenolol	Indenolol may increase the bradycardic activities of Anvirzel.	Withdrawn
Indirubin	Anvirzel may decrease the cardiotoxic activities of Indirubin.	Investigational
Infigratinib	Anvirzel may decrease the cardiotoxic activities of Bgj398.	Investigational
INNO-206	The serum concentration of Anvirzel can be decreased when it is combined with INNO-206.	Investigational
Interferon beta-1a	Anvirzel may decrease the cardiotoxic activities of Interferon beta-1a.	Approved, Investigational
Interferon beta-1b	Anvirzel may decrease the cardiotoxic activities of Interferon beta-1b.	Approved
Iobenguane	Anvirzel may decrease the cardiotoxic activities of Iobenguane.	Approved
Ipilimumab	Anvirzel may decrease the cardiotoxic activities of Ipilimumab.	Approved
Irinotecan	Anvirzel may decrease the cardiotoxic activities of Irinotecan.	Approved, Investigational
Irofulven	Anvirzel may decrease the cardiotoxic activities of MGI-114.	Investigational
Itraconazole	The serum concentration of Anvirzel can be increased when it is combined with Itraconazole.	Approved, Investigational
Ixabepilone	Anvirzel may decrease the cardiotoxic activities of Ixabepilone.	Approved, Investigational
Ixazomib	Anvirzel may decrease the cardiotoxic activities of Ixazomib.	Approved
Josamycin	The serum concentration of Anvirzel can be increased when it is combined with Josamycin.	Approved
Kanamycin	The serum concentration of Anvirzel can be decreased when it is combined with Kanamycin.	Approved, Vet Approved
Kaolin	The serum concentration of Anvirzel can be decreased when it is combined with Kaolin.	Approved
Kitasamycin	The serum concentration of Anvirzel can be increased when it is combined with Kitasamycin.	Experimental
KOS-1584	Anvirzel may decrease the cardiotoxic activities of KOS-1584.	Investigational
L-alanosine	Anvirzel may decrease the cardiotoxic activities of L-alanosine.	Investigational
L-Eflornithine	Anvirzel may decrease the cardiotoxic activities of Alpha-Difluoromethylornithine.	Experimental
Labetalol	Labetalol may increase the bradycardic activities of Anvirzel.	Approved
Landiolol	Aop200704 may increase the bradycardic activities of Anvirzel.	Investigational
Lanreotide	Anvirzel may decrease the cardiotoxic activities of Lanreotide.	Approved
Lapatinib	Anvirzel may decrease the cardiotoxic activities of Lapatinib.	Approved, Investigational
Leflunomide	Anvirzel may decrease the cardiotoxic activities of Leflunomide.	Approved, Investigational
Lenalidomide	Anvirzel may decrease the cardiotoxic activities of Lenalidomide.	Approved
Lenvatinib	Anvirzel may decrease the cardiotoxic activities of Lenvatinib.	Approved
Letrozole	Anvirzel may decrease the cardiotoxic activities of Letrozole.	Approved, Investigational
Leuprolide	Anvirzel may decrease the cardiotoxic activities of Leuprolide.	Approved, Investigational
Levobunolol	Levobunolol may increase the bradycardic activities of Anvirzel.	Approved
Levofloxacin	Anvirzel may decrease the cardiotoxic activities of Levofloxacin.	Approved, Investigational
Liarozole	Anvirzel may decrease the cardiotoxic activities of Liarozole.	Investigational
Licorice	The risk or severity of adverse effects can be increased when Licorice is combined with Anvirzel.	Approved
Lomefloxacin	Anvirzel may decrease the cardiotoxic activities of Lomefloxacin.	Approved
Lomustine	Anvirzel may decrease the cardiotoxic activities of Lomustine.	Approved
Lonidamine	Anvirzel may decrease the cardiotoxic activities of Lonidamine.	Approved, Investigational
Lycopene	Anvirzel may decrease the cardiotoxic activities of Lycopene.	Approved
Mafosfamide	Anvirzel may decrease the cardiotoxic activities of Mafosfamide.	Investigational
Masitinib	Anvirzel may decrease the cardiotoxic activities of Masitinib.	Vet Approved
Masoprocol	Anvirzel may decrease the cardiotoxic activities of Masoprocol.	Approved
Maxacalcitol	Anvirzel may decrease the cardiotoxic activities of Maxacalcitol.	Approved
Mebendazole	Anvirzel may decrease the cardiotoxic activities of Mebendazole.	Approved, Vet Approved
Mechlorethamine	Anvirzel may decrease the cardiotoxic activities of Mechlorethamine.	Approved
Medrogestone	Anvirzel may decrease the cardiotoxic activities of Medrogestone.	Approved
Medroxyprogesterone acetate	Anvirzel may decrease the cardiotoxic activities of Medroxyprogesterone acetate.	Approved, Investigational
Megestrol acetate	Anvirzel may decrease the cardiotoxic activities of Megestrol acetate.	Approved, Vet Approved
Melphalan	Anvirzel may decrease the cardiotoxic activities of Melphalan.	Approved
Mequinol	Anvirzel may decrease the cardiotoxic activities of Mequinol.	Approved
Mercaptopurine	Anvirzel may decrease the cardiotoxic activities of Mercaptopurine.	Approved
Merestinib	Anvirzel may decrease the cardiotoxic activities of Ly2801653.	Investigational
Mesalazine	The serum concentration of Anvirzel can be decreased when it is combined with Mesalazine.	Approved
Methimazole	The serum concentration of Anvirzel can be increased when it is combined with Methimazole.	Approved
Methotrexate	Anvirzel may decrease the cardiotoxic activities of Methotrexate.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Anvirzel.	Approved
Methyl aminolevulinate	Anvirzel may decrease the cardiotoxic activities of Methyl aminolevulinate.	Approved
Methylprednisolone	Anvirzel may decrease the cardiotoxic activities of Methylprednisolone.	Approved, Vet Approved
Methyltestosterone	Anvirzel may decrease the cardiotoxic activities of Methyltestosterone.	Approved
Metipranolol	Metipranolol may increase the bradycardic activities of Anvirzel.	Approved
Metocurine	Metocurine may increase the arrhythmogenic activities of Anvirzel.	Approved
Metocurine Iodide	Metocurine Iodide may increase the arrhythmogenic activities of Anvirzel.	Withdrawn
Metolazone	The risk or severity of adverse effects can be increased when Metolazone is combined with Anvirzel.	Approved
Metoprolol	Metoprolol may increase the bradycardic activities of Anvirzel.	Approved, Investigational
Metrizamide	The serum concentration of Anvirzel can be decreased when it is combined with Metrizamide.	Approved
Midodrine	Anvirzel may increase the bradycardic activities of Midodrine.	Approved
Midostaurin	Anvirzel may decrease the cardiotoxic activities of Midostaurin.	Approved
Miltefosine	Anvirzel may decrease the cardiotoxic activities of Miltefosine.	Approved
Misonidazole	Anvirzel may decrease the cardiotoxic activities of Misonidazole.	Investigational
Mitoguazone	Anvirzel may decrease the cardiotoxic activities of Mitoguazone.	Investigational
Mitolactol	Anvirzel may decrease the cardiotoxic activities of Mitolactol.	Investigational
Mitomycin	Anvirzel may decrease the cardiotoxic activities of Mitomycin.	Approved
Mitotane	Anvirzel may decrease the cardiotoxic activities of Mitotane.	Approved
Mitoxantrone	Anvirzel may decrease the cardiotoxic activities of Mitoxantrone.	Approved, Investigational
Mivacurium	Mivacurium may increase the arrhythmogenic activities of Anvirzel.	Approved
Mizoribine	Anvirzel may decrease the cardiotoxic activities of Mizoribine.	Investigational
MLN576	Anvirzel may decrease the cardiotoxic activities of MLN576.	Investigational
Molgramostim	Anvirzel may decrease the cardiotoxic activities of Molgramostim.	Investigational
motexafin gadolinium	Anvirzel may decrease the cardiotoxic activities of motexafin gadolinium.	Investigational
Moxifloxacin	Anvirzel may decrease the cardiotoxic activities of Moxifloxacin.	Approved, Investigational
Mycophenolic acid	Anvirzel may decrease the cardiotoxic activities of Mycophenolic acid.	Approved
Nadolol	Nadolol may increase the bradycardic activities of Anvirzel.	Approved
Nalidixic Acid	Anvirzel may decrease the cardiotoxic activities of Nalidixic Acid.	Approved
Namitecan	Anvirzel may decrease the cardiotoxic activities of Namitecan.	Investigational
Navitoclax	Anvirzel may decrease the cardiotoxic activities of Navitoclax.	Investigational
Neamine	The serum concentration of Anvirzel can be decreased when it is combined with Neamine.	Experimental
Nebularine	Anvirzel may decrease the cardiotoxic activities of Purine Riboside.	Experimental
Necitumumab	Anvirzel may decrease the cardiotoxic activities of Necitumumab.	Approved
Nelarabine	Anvirzel may decrease the cardiotoxic activities of Nelarabine.	Approved, Investigational
Neomycin	The serum concentration of Anvirzel can be decreased when it is combined with Neomycin.	Approved, Vet Approved
Neosaxitoxin	Neosaxitoxin may increase the arrhythmogenic activities of Anvirzel.	Investigational
Netilmicin	The serum concentration of Anvirzel can be decreased when it is combined with Netilmicin.	Approved
Niguldipine	Anvirzel may decrease the cardiotoxic activities of Niguldipine.	Experimental
Nilotinib	Anvirzel may decrease the cardiotoxic activities of Nilotinib.	Approved, Investigational
Nilutamide	Anvirzel may decrease the cardiotoxic activities of Nilutamide.	Approved
Nimustine	Anvirzel may decrease the cardiotoxic activities of Nimustine.	Investigational
Nintedanib	Anvirzel may decrease the cardiotoxic activities of Nintedanib.	Approved
Nivolumab	Anvirzel may decrease the cardiotoxic activities of Nivolumab.	Approved
nocodazole	Anvirzel may decrease the cardiotoxic activities of nocodazole.	Experimental
Nolatrexed	Anvirzel may decrease the cardiotoxic activities of Nolatrexed.	Investigational
Norfloxacin	Anvirzel may decrease the cardiotoxic activities of Norfloxacin.	Approved
Obinutuzumab	Anvirzel may decrease the cardiotoxic activities of Obinutuzumab.	Approved
Octreotide	Anvirzel may decrease the cardiotoxic activities of Octreotide.	Approved, Investigational
Ofatumumab	Anvirzel may decrease the cardiotoxic activities of Ofatumumab.	Approved
Ofloxacin	Anvirzel may decrease the cardiotoxic activities of Ofloxacin.	Approved
Olaparib	Anvirzel may decrease the cardiotoxic activities of Olaparib.	Approved
Oleandomycin	The serum concentration of Anvirzel can be increased when it is combined with Oleandomycin.	Vet Approved
Olsalazine	The serum concentration of Anvirzel can be decreased when it is combined with Olsalazine.	Approved
Omacetaxine mepesuccinate	Anvirzel may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.	Approved
Oprelvekin	Anvirzel may decrease the cardiotoxic activities of Oprelvekin.	Approved, Investigational
Osimertinib	Anvirzel may decrease the cardiotoxic activities of Osimertinib.	Approved
Oxaliplatin	Anvirzel may decrease the cardiotoxic activities of Oxaliplatin.	Approved, Investigational
Oxprenolol	Oxprenolol may increase the bradycardic activities of Anvirzel.	Approved
Paclitaxel	Anvirzel may decrease the cardiotoxic activities of Paclitaxel.	Approved, Vet Approved
Palbociclib	Anvirzel may decrease the cardiotoxic activities of Palbociclib.	Approved
Palifosfamide	Anvirzel may decrease the cardiotoxic activities of Palifosfamide.	Investigational
Pamidronate	Anvirzel may decrease the cardiotoxic activities of Pamidronate.	Approved
Pancuronium	Pancuronium may increase the arrhythmogenic activities of Anvirzel.	Approved
Panitumumab	Anvirzel may decrease the cardiotoxic activities of Panitumumab.	Approved, Investigational
Panobinostat	Anvirzel may decrease the cardiotoxic activities of Panobinostat.	Approved, Investigational
Parathyroid hormone	The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Anvirzel.	Approved, Investigational
Paricalcitol	Paricalcitol may increase the arrhythmogenic activities of Anvirzel.	Approved, Investigational
Paromomycin	The serum concentration of Anvirzel can be decreased when it is combined with Paromomycin.	Approved, Investigational
Patupilone	Anvirzel may decrease the cardiotoxic activities of Epothilone B.	Experimental, Investigational
Pazopanib	Anvirzel may decrease the cardiotoxic activities of Pazopanib.	Approved
Pazufloxacin	Anvirzel may decrease the cardiotoxic activities of Pazufloxacin.	Investigational
Pefloxacin	Anvirzel may decrease the cardiotoxic activities of Pefloxacin.	Approved
Pegaspargase	Anvirzel may decrease the cardiotoxic activities of Pegaspargase.	Approved, Investigational
Pembrolizumab	Anvirzel may decrease the cardiotoxic activities of Pembrolizumab.	Approved
Pemetrexed	Anvirzel may decrease the cardiotoxic activities of Pemetrexed.	Approved, Investigational
Penbutolol	Penbutolol may increase the bradycardic activities of Anvirzel.	Approved, Investigational
Penclomedine	Anvirzel may decrease the cardiotoxic activities of Penclomedine.	Investigational
Pentostatin	Anvirzel may decrease the cardiotoxic activities of Pentostatin.	Approved, Investigational
Pertuzumab	Anvirzel may decrease the cardiotoxic activities of Pertuzumab.	Approved
Phenylacetic acid	Anvirzel may decrease the cardiotoxic activities of Phenylacetic acid.	Approved
Phenylbutyric acid	Anvirzel may decrease the cardiotoxic activities of Sodium phenylbutyrate.	Approved, Investigational
Pindolol	Pindolol may increase the bradycardic activities of Anvirzel.	Approved
Pipecuronium	Pipecuronium may increase the arrhythmogenic activities of Anvirzel.	Approved
Pipobroman	Anvirzel may decrease the cardiotoxic activities of Pipobroman.	Approved
Pirarubicin	Anvirzel may decrease the cardiotoxic activities of Pirarubicin.	Investigational
Piretanide	The risk or severity of adverse effects can be increased when Piretanide is combined with Anvirzel.	Experimental
Pirfenidone	Anvirzel may decrease the cardiotoxic activities of Pirfenidone.	Investigational
Pirlindole	Anvirzel may decrease the cardiotoxic activities of Pirlindole.	Approved
Pixantrone	Anvirzel may decrease the cardiotoxic activities of Pixantrone.	Investigational
Plevitrexed	Anvirzel may decrease the cardiotoxic activities of Plevitrexed.	Investigational
Plicamycin	Anvirzel may decrease the cardiotoxic activities of Plicamycin.	Approved, Withdrawn
Podofilox	Anvirzel may decrease the cardiotoxic activities of Podofilox.	Approved
Podophyllin	Anvirzel may decrease the cardiotoxic activities of Podophyllin.	Approved
Polythiazide	The risk or severity of adverse effects can be increased when Polythiazide is combined with Anvirzel.	Approved
Pomalidomide	Anvirzel may decrease the cardiotoxic activities of Pomalidomide.	Approved
Ponatinib	Anvirzel may decrease the cardiotoxic activities of Ponatinib.	Approved
Porfimer sodium	Anvirzel may decrease the cardiotoxic activities of Porfimer.	Approved, Investigational
porfiromycin	Anvirzel may decrease the cardiotoxic activities of porfiromycin.	Investigational
Practolol	Practolol may increase the bradycardic activities of Anvirzel.	Approved
Pralatrexate	Anvirzel may decrease the cardiotoxic activities of Pralatrexate.	Approved
Prednimustine	Anvirzel may decrease the cardiotoxic activities of Prednimustine.	Investigational
Prednisolone	Anvirzel may decrease the cardiotoxic activities of Prednisolone.	Approved, Vet Approved
Prednisone	Anvirzel may decrease the cardiotoxic activities of Prednisone.	Approved, Vet Approved
Primaquine	The serum concentration of Anvirzel can be increased when it is combined with Primaquine.	Approved
Procarbazine	Anvirzel may decrease the cardiotoxic activities of Procarbazine.	Approved
Propafenone	The serum concentration of Anvirzel can be increased when it is combined with Propafenone.	Approved
Propranolol	Propranolol may increase the bradycardic activities of Anvirzel.	Approved, Investigational
Propylthiouracil	The serum concentration of Anvirzel can be increased when it is combined with Propylthiouracil.	Approved
Puromycin	Anvirzel may decrease the cardiotoxic activities of Puromycin.	Experimental
Pyrantel	Pyrantel may increase the arrhythmogenic activities of Anvirzel.	Approved, Vet Approved
Pyrazoloacridine	Anvirzel may decrease the cardiotoxic activities of Pyrazoloacridine.	Investigational
Quinacrine	Anvirzel may decrease the cardiotoxic activities of Quinacrine.	Approved
Quinethazone	The risk or severity of adverse effects can be increased when Quinethazone is combined with Anvirzel.	Approved
Quinidine	The serum concentration of Anvirzel can be increased when it is combined with Quinidine.	Approved
Radium Ra 223 Dichloride	Anvirzel may decrease the cardiotoxic activities of Radium Ra 223 Dichloride.	Approved, Investigational
Raltitrexed	Anvirzel may decrease the cardiotoxic activities of Raltitrexed.	Approved, Investigational
Ramucirumab	Anvirzel may decrease the cardiotoxic activities of Ramucirumab.	Approved, Investigational
Ranibizumab	Anvirzel may decrease the cardiotoxic activities of Ranibizumab.	Approved
Ranpirnase	Anvirzel may decrease the cardiotoxic activities of Ranpirnase.	Investigational
Rapacuronium	Rapacuronium may increase the arrhythmogenic activities of Anvirzel.	Withdrawn
Regorafenib	Anvirzel may decrease the cardiotoxic activities of Regorafenib.	Approved
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Anvirzel.	Approved
Resveratrol	Anvirzel may decrease the cardiotoxic activities of Resveratrol.	Experimental, Investigational
Rhodamine 6G	Anvirzel may decrease the cardiotoxic activities of Rhodamine 6G.	Experimental
Ribostamycin	The serum concentration of Anvirzel can be decreased when it is combined with Ribostamycin.	Approved
Rituximab	Anvirzel may decrease the cardiotoxic activities of Rituximab.	Approved
Rocuronium	Rocuronium may increase the arrhythmogenic activities of Anvirzel.	Approved
Romidepsin	Anvirzel may decrease the cardiotoxic activities of Romidepsin.	Approved, Investigational
Romiplostim	Anvirzel may decrease the cardiotoxic activities of Romiplostim.	Approved
Roquinimex	Anvirzel may decrease the cardiotoxic activities of Roquinimex.	Investigational
Rubitecan	Anvirzel may decrease the cardiotoxic activities of Rubitecan.	Investigational
Rucaparib	Anvirzel may decrease the cardiotoxic activities of Rucaparib.	Approved, Investigational
Ruxolitinib	Anvirzel may decrease the cardiotoxic activities of Ruxolitinib.	Approved
Salirasib	Anvirzel may decrease the cardiotoxic activities of Salirasib.	Investigational
Saracatinib	Anvirzel may decrease the cardiotoxic activities of Saracatinib.	Investigational
Satraplatin	Anvirzel may decrease the cardiotoxic activities of Satraplatin.	Investigational
Seliciclib	Anvirzel may decrease the cardiotoxic activities of Seliciclib.	Investigational
Semaxanib	Anvirzel may decrease the cardiotoxic activities of Semaxanib.	Investigational
Seocalcitol	Anvirzel may decrease the cardiotoxic activities of Seocalcitol.	Experimental
Siltuximab	Anvirzel may decrease the cardiotoxic activities of Siltuximab.	Approved
Sirolimus	Anvirzel may decrease the cardiotoxic activities of Sirolimus.	Approved, Investigational
Sisomicin	The serum concentration of Anvirzel can be decreased when it is combined with Sisomicin.	Investigational
Sizofiran	Anvirzel may decrease the cardiotoxic activities of Sonifilan.	Investigational
Solithromycin	The serum concentration of Anvirzel can be increased when it is combined with Solithromycin.	Investigational
Sonidegib	Anvirzel may decrease the cardiotoxic activities of Sonidegib.	Approved, Investigational
Sorafenib	Anvirzel may decrease the cardiotoxic activities of Sorafenib.	Approved, Investigational
Sotalol	Sotalol may increase the bradycardic activities of Anvirzel.	Approved
SP1049C	The serum concentration of Anvirzel can be decreased when it is combined with SP1049C.	Investigational
Sparfloxacin	Anvirzel may decrease the cardiotoxic activities of Sparfloxacin.	Approved
Sparfosic acid	Anvirzel may decrease the cardiotoxic activities of Sparfosic acid.	Experimental
Sparsomycin	Anvirzel may decrease the cardiotoxic activities of Sparsomycin.	Experimental
Spectinomycin	The serum concentration of Anvirzel can be decreased when it is combined with Spectinomycin.	Approved, Vet Approved
Spiramycin	The serum concentration of Anvirzel can be increased when it is combined with Spiramycin.	Approved
Spironolactone	The therapeutic efficacy of Anvirzel can be decreased when used in combination with Spironolactone.	Approved
squalamine	Anvirzel may decrease the cardiotoxic activities of squalamine.	Investigational
SRT501	Anvirzel may decrease the cardiotoxic activities of SRT501.	Investigational
Streptomycin	The serum concentration of Anvirzel can be decreased when it is combined with Streptomycin.	Approved, Vet Approved
Streptozocin	Anvirzel may decrease the cardiotoxic activities of Streptozocin.	Approved
Succinylcholine	Succinylcholine may increase the arrhythmogenic activities of Anvirzel.	Approved
Sulfasalazine	The serum concentration of Anvirzel can be decreased when it is combined with Sulfasalazine.	Approved
Sulforaphane	Anvirzel may decrease the cardiotoxic activities of Sulforaphane.	Investigational
Sulindac	Anvirzel may decrease the cardiotoxic activities of Sulindac.	Approved
Sulpiride	The risk or severity of adverse effects can be increased when Sulpiride is combined with Anvirzel.	Approved
Sunitinib	Anvirzel may decrease the cardiotoxic activities of Sunitinib.	Approved, Investigational
Suramin	Anvirzel may decrease the cardiotoxic activities of Suramin.	Approved
Talaporfin	Anvirzel may decrease the cardiotoxic activities of Talaporfin.	Investigational
Talazoparib	Anvirzel may decrease the cardiotoxic activities of Bmn 673.	Investigational
Tamoxifen	Anvirzel may decrease the cardiotoxic activities of Tamoxifen.	Approved
Tegafur	Anvirzel may decrease the cardiotoxic activities of Tegafur.	Approved
Telithromycin	The serum concentration of Anvirzel can be increased when it is combined with Telithromycin.	Approved
Telmisartan	The serum concentration of Anvirzel can be increased when it is combined with Telmisartan.	Approved, Investigational
Temafloxacin	Anvirzel may decrease the cardiotoxic activities of Temafloxacin.	Withdrawn
Temoporfin	Anvirzel may decrease the cardiotoxic activities of Temoporfin.	Approved
Temozolomide	Anvirzel may decrease the cardiotoxic activities of Temozolomide.	Approved, Investigational
Temsirolimus	Anvirzel may decrease the cardiotoxic activities of Temsirolimus.	Approved
Teniposide	Anvirzel may decrease the cardiotoxic activities of Teniposide.	Approved
Testolactone	Anvirzel may decrease the cardiotoxic activities of Testolactone.	Approved
Tezacitabine	Anvirzel may decrease the cardiotoxic activities of Tezacitabine.	Investigational
Thalidomide	Anvirzel may decrease the cardiotoxic activities of Thalidomide.	Approved, Investigational, Withdrawn
Thiotepa	Anvirzel may decrease the cardiotoxic activities of Thiotepa.	Approved
Thymalfasin	Anvirzel may decrease the cardiotoxic activities of Thymalfasin.	Approved, Investigational
Tibolone	Anvirzel may decrease the cardiotoxic activities of Tibolone.	Approved
Timolol	Timolol may increase the bradycardic activities of Anvirzel.	Approved
Tioguanine	Anvirzel may decrease the cardiotoxic activities of Tioguanine.	Approved
Tiomolibdate ion	Anvirzel may decrease the cardiotoxic activities of Tetrathiomolybdate.	Investigational
Tipifarnib	Anvirzel may decrease the cardiotoxic activities of Tipifarnib.	Investigational
Tirapazamine	Anvirzel may decrease the cardiotoxic activities of Tirapazamine.	Investigational
Tivozanib	Anvirzel may decrease the cardiotoxic activities of Tivozanib.	Investigational
Tobramycin	The serum concentration of Anvirzel can be decreased when it is combined with Tobramycin.	Approved, Investigational
Tolevamer	The risk or severity of adverse effects can be increased when Polystyrene sulfonate is combined with Anvirzel.	Approved
Topotecan	Anvirzel may decrease the cardiotoxic activities of Topotecan.	Approved, Investigational
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Anvirzel.	Approved
Toremifene	Anvirzel may decrease the cardiotoxic activities of Toremifene.	Approved, Investigational
Tositumomab	Anvirzel may decrease the cardiotoxic activities of Tositumomab.	Approved
Trabectedin	Anvirzel may decrease the cardiotoxic activities of Trabectedin.	Approved, Investigational
Trametinib	Anvirzel may decrease the cardiotoxic activities of Trametinib.	Approved
Trastuzumab	Anvirzel may decrease the cardiotoxic activities of Trastuzumab.	Approved, Investigational
Trastuzumab emtansine	Anvirzel may decrease the cardiotoxic activities of Trastuzumab emtansine.	Approved
Trebananib	Anvirzel may decrease the cardiotoxic activities of Amg 386.	Investigational
Treosulfan	Anvirzel may decrease the cardiotoxic activities of Treosulfan.	Investigational
Tretazicar	Anvirzel may decrease the cardiotoxic activities of CB1954.	Investigational
Tretinoin	Anvirzel may decrease the cardiotoxic activities of Tretinoin.	Approved, Investigational, Nutraceutical
Triamterene	The therapeutic efficacy of Anvirzel can be decreased when used in combination with Triamterene.	Approved
Trichlormethiazide	The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Anvirzel.	Approved, Vet Approved
Tridolgosir	Anvirzel may decrease the cardiotoxic activities of Swainsonine.	Experimental
Trifluridine	Anvirzel may decrease the cardiotoxic activities of Trifluridine.	Approved
Trilostane	Anvirzel may decrease the cardiotoxic activities of Trilostane.	Approved, Investigational, Vet Approved, Withdrawn
Trimetrexate	Anvirzel may decrease the cardiotoxic activities of Trimetrexate.	Approved, Investigational
Triptorelin	Anvirzel may decrease the cardiotoxic activities of Triptorelin.	Approved, Vet Approved
Trofosfamide	Anvirzel may decrease the cardiotoxic activities of Trofosfamide.	Investigational
Trovafloxacin	Anvirzel may decrease the cardiotoxic activities of Trovafloxacin.	Approved, Withdrawn
Troxacitabine	Anvirzel may decrease the cardiotoxic activities of Troxacitabine.	Investigational
TTNPB	Anvirzel may decrease the cardiotoxic activities of TTNPB.	Experimental
Tubercidin	Anvirzel may decrease the cardiotoxic activities of Tubercidin.	Experimental
Tubocurarine	Tubocurarine may increase the arrhythmogenic activities of Anvirzel.	Approved
Tylosin	The serum concentration of Anvirzel can be increased when it is combined with Tylosin.	Vet Approved
Ubenimex	Anvirzel may decrease the cardiotoxic activities of Ubenimex.	Experimental
Uracil mustard	Anvirzel may decrease the cardiotoxic activities of Uracil mustard.	Approved
Vadimezan	Anvirzel may decrease the cardiotoxic activities of ASA404.	Investigational
Valrubicin	Anvirzel may decrease the cardiotoxic activities of Valrubicin.	Approved
Vandetanib	Anvirzel may decrease the cardiotoxic activities of Vandetanib.	Approved
Vapreotide	Anvirzel may decrease the cardiotoxic activities of Vapreotide.	Approved, Investigational
Vecuronium	Vecuronium may increase the arrhythmogenic activities of Anvirzel.	Approved
Veliparib	Anvirzel may decrease the cardiotoxic activities of Veliparib.	Investigational
Vemurafenib	Anvirzel may decrease the cardiotoxic activities of Vemurafenib.	Approved
Verapamil	Verapamil may increase the atrioventricular blocking (AV block) activities of Anvirzel.	Approved
Verteporfin	Anvirzel may decrease the cardiotoxic activities of Verteporfin.	Approved, Investigational
Vesnarinone	Anvirzel may decrease the cardiotoxic activities of Vesnarinone.	Investigational
Vinblastine	Anvirzel may decrease the cardiotoxic activities of Vinblastine.	Approved
Vincristine	Anvirzel may decrease the cardiotoxic activities of Vincristine.	Approved, Investigational
Vindesine	Anvirzel may decrease the cardiotoxic activities of Vindesine.	Approved
Vinflunine	Anvirzel may decrease the cardiotoxic activities of Vinflunine.	Approved
Vinorelbine	Anvirzel may decrease the cardiotoxic activities of Vinorelbine.	Approved, Investigational
Vismodegib	Anvirzel may decrease the cardiotoxic activities of Vismodegib.	Approved
Vitamin A	Anvirzel may decrease the cardiotoxic activities of Vitamin A.	Approved, Nutraceutical, Vet Approved
Vorinostat	Anvirzel may decrease the cardiotoxic activities of Vorinostat.	Approved, Investigational
Zorubicin	Anvirzel may decrease the cardiotoxic activities of Zorubicin.	Experimental
Zuretinol acetate	Anvirzel may decrease the cardiotoxic activities of Qlt091001.	Investigational

Food Interactions

Not Available

References

Synthesis Reference

Not Available

General References

Not Available

External Links

Resource	Link
ChemSpider	9716290
ChEBI	59030
ChEMBL	CHEMBL1075789
Wikipedia	Oleandrin

ATC Codes

Not Available

AHFS Codes

Not Available

PDB Entries

Not Available

FDA label

Not Available

MSDS

Not Available

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Withdrawn	Treatment	Chemotherapeutic Agent Toxicity / Lung Cancers	1

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00299 mg/mL	ALOGPS
logP	2.1	ALOGPS
logP	2.95	ChemAxon
logS	-5.3	ALOGPS
pKa (Strongest Acidic)	6.82	ChemAxon
pKa (Strongest Basic)	-3.2	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	7	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	120.75 Å²	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	148.45 m³·mol^-1	ChemAxon
Polarizability	63.2 Å³	ChemAxon
Number of Rings	6	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as cardenolide glycosides and derivatives. These are compounds containing a carbohydrate glycosidically bound to the cardenolide moiety.

Kingdom

Organic compounds

Super Class

Lipids and lipid-like molecules

Class

Steroids and steroid derivatives

Sub Class

Steroid lactones

Direct Parent

Cardenolide glycosides and derivatives

Alternative Parents

Steroidal glycosides / Steroid esters / 14-hydroxysteroids / Hexoses / O-glycosyl compounds / Oxanes / Butenolides / Dicarboxylic acids and derivatives / Tertiary alcohols / Enoate esters

Substituents

Cardanolide-glycoside / Steroidal glycoside / Steroid ester / 14-hydroxysteroid / Hydroxysteroid / Hexose monosaccharide / Glycosyl compound / O-glycosyl compound / 2-furanone / Dicarboxylic acid or derivatives

Molecular Framework

Aliphatic heteropolycyclic compounds

External Descriptors

steroid ester, steroid saponin, 14beta-hydroxy steroid, cardenolide glycoside (CHEBI:59030 )

Drug created on October 20, 2016 18:39 / Updated on September 01, 2017 12:25

Structure for DB12843 (Oleandrin)